{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:26:21Z","timestamp":1792743981562,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T00:00:00Z","timestamp":1677283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019203","name":"ImmunoGen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019203","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.gore.2023.101155","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T21:18:55Z","timestamp":1677532735000},"page":"101155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8389-0069","authenticated-orcid":false,"given":"Andrew","family":"Hendershot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Slabaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran M.","family":"Riaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried E.","family":"Konecny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2023.101155_b0130","unstructured":"2020-2021 Basic and Clinical Science Course. Section 3: Clinical Optics. American Academy of Ophthalmology. Accessed October 4, 2022."},{"key":"10.1016\/j.gore.2023.101155_b0005","doi-asserted-by":"crossref","unstructured":"Ab, O., Whiteman, K.R., Bartle, L.M., Sun, X., Singh, R., Tavares, D., et al., 2015. IMGN853, a folate receptor-\u03b1 (FR\u03b1)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FR\u03b1-expressing tumors. Mol. Cancer. Ther 14 (7), 1605\u20131613.","DOI":"10.1158\/1535-7163.MCT-14-1095"},{"issue":"1","key":"10.1016\/j.gore.2023.101155_b0010","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/bjh.18298","article-title":"Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma","volume":"199","author":"Abeykoon","year":"2022","journal-title":"Br. J. Haematol"},{"key":"10.1016\/j.gore.2023.101155_b0015","doi-asserted-by":"crossref","unstructured":"Alves, M., Novaes, P., Morraye Mde, A., Reinach, P.S., Rocha, E.M., 2014. Is dry eye an environmental disease? Arq. Bras. Oftalmol 77 (3), 193\u2013200.","DOI":"10.5935\/0004-2749.20140050"},{"key":"10.1016\/j.gore.2023.101155_b0025","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2022.06.009","article-title":"Corneal toxicity associated with belantamab mafodotin is not restricted to the epithelium: neuropathy studied with confocal microscopy","volume":"242","author":"Aschauer","year":"2022","journal-title":"Am. J. Ophthalmol"},{"key":"10.1016\/j.gore.2023.101155_b0030","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.2147\/DDDT.S151420","article-title":"Variability in the therapeutic management of advanced ovarian cancer patients: a five-country survey of oncologists","volume":"11","author":"Audibert","year":"2017","journal-title":"Drug. Des. Devel. Ther"},{"issue":"4","key":"10.1016\/j.gore.2023.101155_b0035","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1634\/theoncologist.2018-0459","article-title":"Is targeting the folate receptor in ovarian cancer coming of age?","volume":"24","author":"Birrer","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.gore.2023.101155_b0040","unstructured":"Blenrep, 2022. Prescribing information. GlaxoSmithKline."},{"issue":"6","key":"10.1016\/j.gore.2023.101155_b0045","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/ICO.0000000000002934","article-title":"Refractive shifts and changes in corneal curvature associated with antibody-drug conjugates","volume":"41","author":"Canestraro","year":"2022","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.gore.2023.101155_b0050","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.molonc.2011.11.010","article-title":"Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response","volume":"6","author":"Chen","year":"2012","journal-title":"Mol. Oncol"},{"key":"10.1016\/j.gore.2023.101155_b0055","doi-asserted-by":"crossref","unstructured":"Chien, J., Kuang, R., Landen, C., Shridhar, V., 2013. Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Front. Oncol 3, 251.","DOI":"10.3389\/fonc.2013.00251"},{"issue":"5","key":"10.1016\/j.gore.2023.101155_b0060","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease\u2020","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol"},{"issue":"2","key":"10.1016\/j.gore.2023.101155_b0065","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/ICO.0000000000001805","article-title":"Ocular toxicity of mirvetuximab","volume":"38","author":"Corbelli","year":"2019","journal-title":"Cornea"},{"issue":"22","key":"10.1016\/j.gore.2023.101155_b0070","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.gore.2023.101155_b0075","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","article-title":"\u201cPlatinum resistant\u201d ovarian cancer: what is it, who to treat and how to measure benefit?","volume":"133","author":"Davis","year":"2014","journal-title":"Gynecol. Oncol"},{"key":"10.1016\/j.gore.2023.101155_b0160","unstructured":"Dear Health Care Provider Letter (Blenrep). GSK plc. November 22, 2022. Accessed December 16, 2022."},{"issue":"10","key":"10.1016\/j.gore.2023.101155_b0080","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular adverse events associated with antibody-drug conjugates in human clinical trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J. Ocul. Pharmacol. Ther"},{"key":"10.1016\/j.gore.2023.101155_b0295","unstructured":"Elahere, 2022. Prescribing information. ImmunoGen Inc."},{"key":"10.1016\/j.gore.2023.101155_b0085","doi-asserted-by":"crossref","unstructured":"Falzone, L., Scandurra, G., Lombardo, V., Gattuso, G., Lavoro, A., Distefano, A.B., et al., 2021. A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review). Int. J. Oncol 59, 53.","DOI":"10.3892\/ijo.2021.5233"},{"issue":"4","key":"10.1016\/j.gore.2023.101155_b0090","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol. Ther"},{"key":"10.1016\/j.gore.2023.101155_b0095","doi-asserted-by":"crossref","unstructured":"Fu, Z., Li, S., Han, S., Shi, C., Zhang, Y., 2022. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal. Transduct. Target. Ther 7, 93.","DOI":"10.1038\/s41392-022-00947-7"},{"issue":"3","key":"10.1016\/j.gore.2023.101155_b0100","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000369125","article-title":"Association of cryptogenic organizing pneumonia in bilateral anterior uveitis","volume":"5","author":"Fujimoto","year":"2014","journal-title":"Case. Rep. Ophthalmol"},{"issue":"4","key":"10.1016\/j.gore.2023.101155_b0105","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.annonc.2021.12.012","article-title":"Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study","volume":"33","author":"Gazzah","year":"2022","journal-title":"Ann. Oncol"},{"issue":"3","key":"10.1016\/j.gore.2023.101155_b0115","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jtos.2017.05.004","article-title":"TFOS DEWS II iatrogenic report","volume":"15","author":"Gomes","year":"2017","journal-title":"Ocul. Surf"},{"key":"10.1016\/j.gore.2023.101155_b0120","doi-asserted-by":"crossref","unstructured":"Halkia, E., Spiliotis, J., Sugarbaker, P., 2012. Diagnosis and management of peritoneal metastases from ovarian cancer. Gastroenterol. Res. Pract 2012, 541842.","DOI":"10.1155\/2012\/541842"},{"issue":"2","key":"10.1016\/j.gore.2023.101155_b0125","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10549-010-1132-4","article-title":"Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer","volume":"126","author":"Hershman","year":"2011","journal-title":"Breast. Cancer. Res. Treat"},{"issue":"2","key":"10.1016\/j.gore.2023.101155_b0140","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ygyno.2022.02.010","article-title":"Mitigation and management strategies for ocular events associated with tisotumab vedotin","volume":"165","author":"Kim","year":"2022","journal-title":"Gynecol. Oncol"},{"issue":"1","key":"10.1016\/j.gore.2023.101155_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/GCO.0000000000000509","article-title":"Editorial: the potential for precision medicine to improve care and speed the development of new treatments in breast and gynecologic malignancies","volume":"31","author":"Konecny","year":"2019","journal-title":"Curr. Opin. Obstet. Gynecol"},{"issue":"8","key":"10.1016\/j.gore.2023.101155_b0150","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s00417-019-04337-8","article-title":"Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics","volume":"257","author":"Kunkler","year":"2019","journal-title":"Graefes. Arch. Clin. Exp. Ophthalmol"},{"key":"10.1016\/j.gore.2023.101155_b0155","article-title":"Treatment of epithelial ovarian cancer","volume":"371","author":"Kuroki","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.gore.2023.101155_b0165","doi-asserted-by":"crossref","unstructured":"Lheureux, S., Braunstein, M., Oza, A.M., 2019. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA. Cancer. J. Clin 69 (4), 280\u2013304.","DOI":"10.3322\/caac.21559"},{"issue":"7","key":"10.1016\/j.gore.2023.101155_b0170","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40264-021-01069-9","article-title":"Risk minimization of antibody-drug conjugates in oncology: A review","volume":"44","author":"Lievano","year":"2021","journal-title":"Drug. Saf"},{"key":"10.1016\/j.gore.2023.101155_b0175","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2147\/OPTH.S299141","article-title":"Management of persistent corneal epithelial defects with human amniotic membrane-derived dry matrix","volume":"15","author":"Maqsood","year":"2021","journal-title":"Clin. Ophthalmol"},{"key":"10.1016\/j.gore.2023.101155_b0180","doi-asserted-by":"crossref","unstructured":"Marquant, K., Quinquenel, A., Arndt, C., Denoyer, A., 2021. Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report. J. Hematol. Oncol 14, 159.","DOI":"10.1186\/s13045-021-01172-5"},{"issue":"1","key":"10.1016\/j.gore.2023.101155_b0185","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Invest. New. Drugs"},{"key":"10.1016\/j.gore.2023.101155_b0190","article-title":"Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography","volume":"23","author":"Matsumiya","year":"2021","journal-title":"Am. J. Ophthalmol. Case. Rep"},{"issue":"6","key":"10.1016\/j.gore.2023.101155_b0195","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1158\/1078-0432.CCR-18-2474","article-title":"Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody-drug conjugate mirvetuximab soravtansine","volume":"25","author":"Matulonis","year":"2019","journal-title":"Clin. Cancer. Res"},{"key":"10.1016\/j.gore.2023.101155_b0215","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","author":"Matulonis","year":"2023","journal-title":"J. Clin. Oncol [online ahead of print]"},{"key":"10.1016\/j.gore.2023.101155_b0220","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.01900","article-title":"[Supplementary Appendix. SORAYA Protocol] Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","author":"Matulonis","year":"2023","journal-title":"J. Clin. Oncol [online ahead of print]"},{"key":"10.1016\/j.gore.2023.101155_b0210","doi-asserted-by":"crossref","unstructured":"Matulonis, U.A., Moore, K.N., Lorusso, D., Oaknin, A., Pignata, S., Denys, H., et al., 2022. Exposure-response analysis for efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with folate receptor alpha-positive cancer. Poster presented at: European Society for Medical Oncology Congress 2022; September 9-13, 2022; Paris, France. Available at https:\/\/www.immunogen.com\/wp-content\/uploads\/2022\/09\/ESMO-Ab592p-ER-Poster-FINAL.pdf.","DOI":"10.1016\/j.annonc.2022.07.720"},{"key":"10.1016\/j.gore.2023.101155_b0200","unstructured":"Matulonis, U.A., Oaknin, A., Pignata, S., Denys, H., Colombo, N., Van Gorp, T., et al., 2022. Mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: characterization of anti-tumor activity in the SORAYA study. Poster presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022; Chicago, IL. Available at https:\/\/www.immunogen.com\/wp-content\/uploads\/2022\/05\/ASCO-2022_SORAYA-120-Day-Poster_51622_vF.pdf."},{"issue":"suppl 16","key":"10.1016\/j.gore.2023.101155_b0205","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1200\/JCO.2022.40.16_suppl.5512","article-title":"Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FR\u03b1) expression: Characterization of antitumor activity in the SORAYA study","volume":"40","author":"Matulonis","year":"2022","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.gore.2023.101155_b0290","unstructured":"Mirvetuximab soravtansine monotherapy in platinum-sensitive epithelial, peritoneal, and fallopian tube cancers (PICCOLO). ClinicalTrials.gov identifier NCT05041257. Updated July 27, 2022. Accessed September 23, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05041257."},{"key":"10.1016\/j.gore.2023.101155_b0110","unstructured":"Mirvetuximab soravtansine with bevacizumab versus bevacizumab as maintenance in platinum-sensitive ovarian, fallopian tube, or peritoneal cancer (GLORIOSA). ClinicalTrials.gov identifier NCT05445778. Updated September 6, 2022. Accessed September 23, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05445778."},{"issue":"16","key":"10.1016\/j.gore.2023.101155_b0235","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1002\/cncr.30736","article-title":"Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in patients with solid tumors","volume":"123","author":"Moore","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.gore.2023.101155_b0245","unstructured":"Moore, K.N., Lorusso, D., Oaknin, A., Oza, A., Colombo, N., Van Gorp, T., et al., 2022. Integrated safety summary of single-agent mirvetuximab soravtansine in patients with folate receptor alpha (FR\u03b1)-positive recurrent ovarian cancer: Phase 1 and 3 clinical trials. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022; Chicago, IL. Available at https:\/\/www.immunogen.com\/wp-content\/uploads\/2022\/05\/ASCO-2022_Integrated-Safety-Poster_51622_vF.pdf."},{"key":"10.1016\/j.gore.2023.101155_b0240","unstructured":"Moore, K.N., Martin, L.P., Matulonis, U.A., 2016. IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC): single agent activity in platinum-resistant epithelial ovarian cancer (EOC) patients. Presented at: 2016 American Society of Clinical Oncology Annual Meeting; June 3-7, 2016; Chicago, IL. Available at https:\/\/www.immunogen.com\/wp-content\/uploads\/2015\/04\/ASCO2016MIRVPH1AB5567.pdf."},{"key":"10.1016\/j.gore.2023.101155_b0230","doi-asserted-by":"crossref","unstructured":"Moore, K.N., Martin, L.P., O\u2019Malley, D.M., Matulonis, U.A., Konner, J.A., Perez, R.P., et al., 2017. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. J. Clin. Oncol 35 (10), 1112\u20131118.","DOI":"10.1200\/JCO.2016.69.9538"},{"issue":"2","key":"10.1016\/j.gore.2023.101155_b0250","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/fon-2017-0379","article-title":"A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer","volume":"14","author":"Moore","year":"2018","journal-title":"Future. Oncol"},{"key":"10.1016\/j.gore.2023.101155_b0260","unstructured":"Moshirfar, M., Bennett, P., Ronquillo, Y., 2021. Corneal dystrophy. StatPearls website. Updated August 11, 2021. Accessed September 23, 2022. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557865."},{"key":"10.1016\/j.gore.2023.101155_b0265","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 5. US Department of Health and Human Services; 2017. Published November 27, 2017. Accessed July 30, 2022. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"issue":"5","key":"10.1016\/j.gore.2023.101155_b0275","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/jjco\/hyt030","article-title":"Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck","volume":"43","author":"Okano","year":"2013","journal-title":"Jpn. J. Clin. Oncol"},{"issue":"2","key":"10.1016\/j.gore.2023.101155_b0280","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40123-017-0110-x","article-title":"Use of the controlled adverse environment (CAE) in clinical research: a review","volume":"6","author":"Ousler","year":"2017","journal-title":"Ophthalmol. Ther"},{"key":"10.1016\/j.gore.2023.101155_b0020","unstructured":"An overview of ocular adverse events associated with the use of Blenrep. GSK. 2022. Accessed September 23, 2022. https:\/\/www.blenrephcp.com\/content\/dam\/cf-pharma\/hcp-blenrephcp-v3\/en_US\/pdf\/occular-mgmt-resources\/PM-US-BLM-OGM-220019.pdf."},{"key":"10.1016\/j.gore.2023.101155_b0285","unstructured":"Padcev, 2022. Prescribing information. Seagen Inc."},{"issue":"12","key":"10.1016\/j.gore.2023.101155_b0300","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1080\/14737159.2016.1259069","article-title":"The rise of genomic profiling in ovarian cancer","volume":"16","author":"Previs","year":"2016","journal-title":"Expert. Rev. Mol. Diagn"},{"key":"10.1016\/j.gore.2023.101155_b0305","doi-asserted-by":"crossref","unstructured":"Puig, M., Weiss, M., Salinas, R., Johnson, D.A., Kheirkhah, A., 2020. Etiology and risk factors for infectious keratitis in South Texas. J. Ophthalmic. Vis. Res 15 (2), 128\u2013137.","DOI":"10.18502\/jovr.v15i2.6729"},{"key":"10.1016\/j.gore.2023.101155_b0310","doi-asserted-by":"crossref","unstructured":"Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., et al., 2014. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J. Clin. Oncol 32(13), 1302\u20131308.","DOI":"10.1200\/JCO.2013.51.4489"},{"issue":"suppl 16","key":"10.1016\/j.gore.2023.101155_b0315","doi-asserted-by":"crossref","first-page":"9039","DOI":"10.1200\/JCO.2022.40.16_suppl.9039","article-title":"Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with nonsquamous non\u2013small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)","volume":"40","author":"Ricordel","year":"2022","journal-title":"J. Clin. Oncol"},{"issue":"4","key":"10.1016\/j.gore.2023.101155_b0320","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jtos.2018.06.004","article-title":"Current and emerging therapies for corneal neovascularization","volume":"16","author":"Roshandel","year":"2018","journal-title":"Ocul. Surf"},{"issue":"1","key":"10.1016\/j.gore.2023.101155_b0325","doi-asserted-by":"crossref","first-page":"e000943","DOI":"10.1136\/bmjophth-2021-000943","article-title":"Drug-induced corneal deposits: an up-to-date review.","volume":"7","author":"Sahyoun","year":"2022","journal-title":"BMJ. Open. Ophthalmol"},{"key":"10.1016\/j.gore.2023.101155_b0330","unstructured":"Shandiz, J.H., Derakhshan, A., Daneshyar, A., Azimi, A., Moghaddam, H.O., Yekta, A.A., et al., 2011. Effect of cataract type and severity on visual acuity and contrast sensitivity. J. Ophthalmic. Vis. Res 6 (1), 26\u201331."},{"issue":"3","key":"10.1016\/j.gore.2023.101155_b0335","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II epidemiology report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul. Surf"},{"key":"10.1016\/j.gore.2023.101155_b0270","unstructured":"Study of carboplatin and mirvetuximab soravtansine in first-line treatment of patients receiving neoadjuvant chemotherapy with advanced-stage ovarian, fallopian tube or primary peritoneal cancer. ClinicalTrials.gov identifier: NCT04606914. Updated July 1, 2022. Accessed September 21, 2022. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04606914."},{"key":"10.1016\/j.gore.2023.101155_b0225","unstructured":"A study of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression (MIRASOL). ClinicalTrials.gov identifier NCT04209855. Updated June 16, 2022. Accessed September 23, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04209855."},{"key":"10.1016\/j.gore.2023.101155_b0340","unstructured":"Tivdak, 2022. Prescribing information. Seagen Inc."},{"key":"10.1016\/j.gore.2023.101155_b0345","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. NDA\/BLA Multi-disciplinary Review and Evaluation. BLA761137. Enfortumab vedotin-ievx. Updated December 17, 2019. Accessed January 14, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761137Orig1s000MultiDiscliplineR.pdf."},{"key":"10.1016\/j.gore.2023.101155_b0350","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. NDA\/BLA Multi-disciplinary Review and Evaluation. BLA761158. Belantamab mafodotin. Updated August 5, 2020. Accessed June 28, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/761158Orig1s000MultidisciplineR.pdf."},{"key":"10.1016\/j.gore.2023.101155_b0355","doi-asserted-by":"crossref","unstructured":"Wahab, A., Rafae, A., Mushtaq, K., Masood, A., Ehsan, H., Khakwani, M., et al., 2021. Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma. Front. Oncol 11, 678634.","DOI":"10.3389\/fonc.2021.678634"},{"issue":"8","key":"10.1016\/j.gore.2023.101155_b0360","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-17-3202","article-title":"Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates","volume":"78","author":"Zhao","year":"2018","journal-title":"Cancer. Res"}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578923000243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578923000243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:58:22Z","timestamp":1762480702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578923000243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":70,"alternative-id":["S2352578923000243"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2023.101155","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2023.101155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101155"}}